Rapport Therapeutics CEO Abraham Ceesay disposes of USD 143,276 in common shares
Bitget2026/10/08 20:07Rapport Therapeutics CEO Abraham Ceesay sold 4,522 common shares on Oct. 6-7. Sales priced at USD 32.0314 per share on Oct. 6, USD 30.66 per share on Oct. 7. Directly held stake fell to 452,245 shares following the Oct. 7 sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-417919), on October 08, 2026, and is solely responsible for the information contained therein.
- Rapport Therapeutics CEO Abraham Ceesay sold 4,522 common shares on Oct. 6-7.
- Sales priced at USD 32.0314 per share on Oct. 6, USD 30.66 per share on Oct. 7.
- Directly held stake fell to 452,245 shares following the Oct. 7 sale.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF
Crypto prices
More
